RVL Pharmaceuticals plc (RVLPQ)

RVL Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2022	2021	2020	2019	2018
Net Income	-51.69	-64.92	-79.59	-270.9	-109.68
Depreciation & Amortization	0.38	8.18	21.03	57.02	81.57
Share-Based Compensation	4.07	7.59	4.93	4.93	1.97
Other Operating Activities	9.44	-5.58	71.23	242.52	63.7
Operating Cash Flow	-37.81	-54.73	17.59	33.57	37.56
Operating Cash Flow Growth	-	-	-47.60%	-10.63%	-35.06%
Capital Expenditures	0.13	-1.69	-3.08	-4.02	-4.13
Acquisitions	0	118.15	0	0	0
Investing Cash Flow	0.13	116.45	-3.08	-4.02	-4.13
Share Issuance / Repurchase	23.83	32.65	54.56	-2.79	58.08
Debt Issued / Paid	18.1	-167.19	-50.13	-1.9	-54.48
Other Financing Activities	-0.14	-0.78	-0.75	-	-0
Financing Cash Flow	41.78	-135.33	3.68	-4.69	3.6
Exchange Rate Effect	0	0	0	0.18	-0.94
Net Cash Flow	4.1	-73.61	18.19	24.86	37.03
Free Cash Flow	-37.68	-56.42	14.51	29.55	33.42
Free Cash Flow Growth	-	-	-50.91%	-11.60%	-34.39%
Free Cash Flow Margin	-75.79%	-322.40%	52.25%	12.31%	12.67%
Free Cash Flow Per Share	-0.42	-0.84	0.24	0.56	0.74

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).